Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 353 East 68th Street, New York, NY 10065, USA.
Hematol Oncol Clin North Am. 2011 Aug;25(4):835-52. doi: 10.1016/j.hoc.2011.04.008.
Better understanding of the molecular biology of renal cell carcinoma (RCC) has led to the development of several targeted anti-cancer agents, several of which have since received approval for treatment of advanced disease. Two of these, the intravenous agent temsirolimus and the oral everolimus, exhibit antitumor effects through inhibition of the mammalian target of rapamycin (mTOR) pathway. This article reviews their mechanisms of action in the context of the current understanding of RCC pathophysiology, the clinical data leading to their approval, class-specific toxicities, potential molecular mechanisms behind treatment resistance and novel treatment approaches for RCC that incorporate mTOR blockade.
更好地理解肾细胞癌（RCC）的分子生物学导致了几种靶向抗癌药物的发展，其中几种药物已被批准用于治疗晚期疾病。其中两种，静脉注射的替西罗莫司和口服的依维莫司，通过抑制哺乳动物雷帕霉素靶蛋白（mTOR）途径发挥抗肿瘤作用。本文综述了它们在目前对 RCC 病理生理学的理解、导致其批准的临床数据、特定于类别的毒性、治疗耐药背后的潜在分子机制以及包含 mTOR 阻断的 RCC 新治疗方法的背景下的作用机制。
